A preleukemic state in mice inoculated with Moloney murine leukemia virus (Mo-MuLV) was characterized. Six to 10 weeks after neonatal inoculation, animals developed mild splenomegaly and generalized hematopoietic hyperplasia. The hyperplasia was evident from myeloid and erythroid progenitor assays. A nonleukemogenic variant, Mo+PyF101 Mo-MuLV, did not induce the hyperplasia; this suggests that the hyperplasia is a necessary event in Mo-MuLV leukemogenesis. Another variant, MF-MuLV, which contains the long terminal repeat of Friend MuLV and causes erythroid leukemia instead of T-cell lymphoma, also induced the preleukemic hyperplasia. A model for Mo-MuLV leukemogenesis is presented in which two infection events are necessary: the first leads to generalized hematopoietic hyperplasia, and the second results in site-specific insertion and long terminal repeat activation of cellular protooncogenes.
Retroviruses that lack oncogenes induce hematopoietic neoplasms with long latency (1) . This long latency may reflect multiple steps in the leukemogenic process. In the case of Moloney murine leukemia virus (Mo-MuLV), which induces T-cell lymphoma, one of these steps is site-specific proviral integration adjacent to cellular protooncogenes (2) (3) (4) (5) . This results in transcriptional activation of the protooncogenes by promoters or enhancers in the viral long terminal repeat (LTR; refs. 2, 3) . In at least some instances, this may be a relatively late event in leukemogenesis (6, 7) . Leukemogenesis may also involve recombination with endogenous retroviral sequences to generate dual-tropic (MCF) MuLVs (7) (8) (9) . The thymotropic enhancers in the Mo-MuLV LTR are also important determinants in the specific type of leukemia (T-lymphoma) induced (10, 11) . Other steps may also be involved in the leukemogenic process.
We have generated Mo-MuLV derivatives that have insertions or substitutions of enhancer sequences from the PyF101 variant of polyomavirus within the Mo-MuLV LTR, Mo+PyF101 and AMo+PyF101, respectively (12, 13) . Neither of these viruses are leukemogenic, although they establish infection in inoculated animals normally. These viruses are minimal variants, since the alterations do not involve protein coding sequences. It is likely that the nonleukemogenicity results from an alteration in the tissue tropism of these viruses such that they are restricted from expression in some critical cell type whose infection is necessary for Mo-MuLV leukemogenesis. Thus, these viruses may allow identification of critical leukemogenic events and target cells. In the experiments presented here, these and other variants of Mo-MuLV were used to identify a preleukemic stage in Mo-MuLV leukemogenesis.
MATERIALS AND METHODS
Viruses and Inoculation of Mice. Generation of wild-type and Mo+PyF101 Mo-MuLV has been described (12) . MFMuLV and FM-MuLV viral stocks (11, 14) were generously provided by Nancy Hopkins. All stocks were culture supernatants from productively infected NIH 3T3 cells. Infectivity titrations were performed by the UV/XC plaque assay (15) . For all experiments, neonatal NIH Swiss or inbred NFS mice were inoculated subcutaneously with 2.5 x 104 XC plaqueforming units (pfu) of virus.
Hematopoietic Colony Assays. Assays for myeloid colonyforming cells (myeloid CFC) and erythroid colony-forming units (CFU-E) were performed essentially according to Metcalf (16) . Myeloid CFC were measured by agar colony assays in medium containing WEHI-3B cell supernatant as a source of growth factors. Colonies (>50 cells) were scored microscopically after 7 days of incubation. CFU-E were measured in methylcellulose colony assays in medium containing concentrated supernatant from pokeweed mitogenstimulated spleen cells and erythropoietin as growth and differentiation factors. CFU-E (densely packed colonies containing a minimum of eight small cells, at least 50% benzidine positive) were scored after 2-3 days.
Infectious Center Assays. Infectious center assays for splenocytes and thymocytes have been described previously (17) . Bone marrow cells were flushed from mouse femurs, passed three or four times through a 23-gauge needle to obtain single cell suspensions, and assayed as for the splenocytes and thymocytes.
RESULTS
The organizations of the MuLVs used in these experiments are shown in Fig. 1 (Tables  1 and 2 ). Mice inoculated with wild-type Mo-MuLV showed a 4-to 10-fold increase in total myeloid colonies (myeloid CFC), and a 10-to 20-fold increase in total erythroid colonies *The criterion for scoring CFU-E was relatively stringent; 20-50 times more colonies showed at least one or two benzidine-positive cells and were potentially CFU-E as well. Thus, absolute numbers appear lower than those reported by others. (Tables 1 and 2 ). This strongly supports the hypothesis that hematopoietic hyperplasia is a necessary early event in Mo-MuLV leukemogenesis. Furthermore, the presumptive cell for which Mo+PyF101 Mo-MuLV is restricted appears to be involved in establishment of the hyperplasia.
Bone marrow from some but not all Mo-MuLV-inoculated animals also showed increases in myeloid CFC. As for the spleen, none of three Mo+PyF101 Mo-MuLV-inoculated mice analyzed showed any increase in bone marrow myeloid CFC (see Table 4 ).
One explanation for the hyperplasia could be an immunological response to Mo-MuLV infection (19 Tables 1 and 2 and in more detail in Table  3 . Many Mo+PyF101 Mo-MuLV-inoculated mice showed high levels of infection, often within 5-fold of the level for a wild-type Mo-MuLV-inoculated animal. Furthermore, when individual Mo+PyF101-inoculated animals were compared, those with high splenocyte infection showed no increases in myeloid colonies, just as for those with low or undetectable splenocyte infection (Tables 1 and 2 ). Thus, the Mo-MuLVinduced hyperplasia does not appear to simply reflect an immune response. However, it is formally possible that a minority population of infected cells are responsible for antigen presentation to the immune system and that Mo+PyF101 Mo-MuLV is defective for expression in them.
The results with Mo+PyF101 Mo-MuLV suggested a model for Mo-MuLV leukemogenesis involving two independent infections (Fig. 2) . The first infection, in the bone marrow or spleen, leads to generalized hematopoietic hyperplasia evident in the spleen (Tables 1 and 2 (Fig. 1) . MF-MuLV causes erythroleukemia due to the specificity of the F-MuLV enhancer sequences, but the virus particles are virtually identical to those of Mo-MuLV. In our conditions, MFMuLV also induced preleukemic splenic enlargement and increase in null cells. The results of myeloid and erythroid colony assays for preleukemic MF-MuLV-inoculated mice (as well as data from wild-type and Mo+PyF101 Mo-MuLVinoculated animals) are summarized in Table 4 . MF-MuLV induced increases in both myeloid and erythroid stem cells in preleukemic spleen, equivalent to that observed for wild-type Mo-MuLV. Importantly, preleukemic spleens from MFMuLV-inoculated mice did not show a significantly larger increase in CFU-E relative to myeloid CFC, even though the virus ultimately caused erythroleukemia. Thus, the F-MuLV enhancer sequences do not appear to change the spectrum of hyperplastic progenitor cells in preleukemic animals. This is consistent with the LTR enhancers exerting their tissuespecific influence on disease specificity at'a second infection event.
Since all of the experiments presented thus far involved variants of Mo-MuLV, it was interesting to test whether other strains of MuLV induce the same kind of preleukemic state. For these experiments, another MuLV derived by Chatis and co-workers (11, 14) was useful: FM-MuLV, Friend MuLV containing a Mo-MuLV LTR (Fig. 1) . This virus induces T-lymphoid leukemia, even though all viral proteins are encoded by F-MuLV. Sitbon et al. (20) recently showed that the env gene of F-MuLV itself induces early erythroid hyperplasia, so CFU-E assays were not performed. However, as shown in Table 4 , FM-MuLV also induces increased myeloid CFC. Thus, the generalized hematopoietic hyperplasia is apparently induced by MuLVs with viral proteins different from M-MuLV.
DISCUSSION
In these experiments, a preleukemic state induced by MoMuLV infection consisting of generalized hematopoietic hyperplasia was documented. Other investigators have described this hyperplasia (18) . However, the failure of nonleukemogenic Mo+PyF101 Mo-MuLV to induce it provides strong evidence that it is a necessary step in the leukemogenic process. These results, coupled with the fact that Mo+PyF101 Mo-MuLV efficiently establishes infection in mature thymocytes, led to a model for Mo-MuLV leukemogenesis involving two independent infections. The model provides a role for MCF derivatives and predicts that tissue specificity of disease results from the second infection event.
The fact that MF-MuLV induced the same hyperplasia as wild-type Mo-MuLV is consistent with disease specificity being determined by the second infection. It seems possible that leukemogenesis by other nonacute retroviruses may involve similar mechanisms. These results are consistent with results of Asjo et al. (21) , who tested for preleukemic cells in Mo-MuLV-inoculated mice by transplantation into irradiated recipients. Preleukemic cells were first detected in the spleen or bone marrow and only at later times in the thymus. This is supportive of the model described here, if the preleukemic cells are related to hyperplastic lymphoid stem cells. The identification of potential preleukemic cells in the bone marrow has also been described for the AKR, F-MuLV, and radiation-induced leukemia virus systems (22) (23) (24) . Infection in vitro of longterm marrow cultures by Mo-MuLV has also been reported to lead to increased myeloid progenitors (25) .
It is unclear whether the critical infection events leading to Mo-MuLV-induced hyperplasia occur in the spleen or bone marrow. In fact, the spleen consistently showed greater increases in concentrations of myeloid and erythroid stem cells than did bone marrow. This suggests that the important infection event occurs in the spleen. Alternatively, the bone marrow could be the main target, but hyperplastic stem cells might migrate to the spleen and undergo proliferation and differentiation. It is also possible that hyperplastic lymphoid stem cells could migrate directly from the bone marrow to the thymus.
The mechanism by which Mo-MuLV induces hematopoietic hyperplasia has yet to be determined. If the preleukemic cells identified by Asjo et al. (21) are related to the increased hematopoietic stem cells described here, this suggests that the preleukemic stem cells are abnormal in some way. Normal spleen or bone marrow (which contain normal hematopoietic progenitors) did not give leukemias in the transplantation experiments (21) .
Preleukemic hyperplasia could result from direct infection by Mo-MuLV of hematopoietic stem cells or alternatively by infection of cells that produce hematopoietic growth factors. Greenberger et al. (25) have reported that Mo-MuLV infection of long-term marrow cultures leads to increased production of the myeloid growth factor colony-stimulating factor. On the other hand, preliminary flow cytometry experiments indicate that a large fraction of cells detected in the myeloid CFC assays are infected, which is consistent with direct infection of stem cells. In any event, both possibilities appear to require growth stimulation by Mo-MuLV, which does not contain an oncogene. Identification of the cell types that are restricted for Mo+PyF101 Mo-MuLV infection will allow more detailed analysis of Mo-MuLV-induced leukemogene-
